Yuko Komase

Yuko Komase

Auto-generated profile, based on publicly available information

Yuko Komase

Department of Respiratory Medicine, St. Marianna University Yokohama Seibu Hospital, Yokohama, Kanagawa, Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2008 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
MIMizuki Ikehara
Mizuki Ikehara
HSHaruhiro Saito
Haruhiro Saito
KYKouzo Yamada
Kouzo Yamada
FOFumihiro Oshita
Fumihiro Oshita
KNKazumasa Noda
Kazumasa Noda
TMTeruomi Miyazawa
Teruomi Miyazawa
We investigated the relationship between findings from tumor opacity in the mediastinal window image and solid lesions in pathological preparations and related the results to tumor recurrence. The subjects were 115 patients with a lung adenocarcinoma of 20 mm or smaller who underwent surgical resection. The proportion of the reduction in the tumor opacity in the mediastinal window image maximum diameter to the maximum diameter of the tumor opacity was calculated as the reduction percentage, and the proportion of the maximum solid lesions in pathological preparation diameter to the maximum tumor diameter was calculated as the pathological ratio. The incidence of relapse was significantly higher in patients with a reduction percentage of less than 50% and in patients with a pathological ratio of less than 50%. Measurement of the reduction percentage and the pathological ratio may allow prediction of prognosis of small adenocarcinoma of the lung.

11 July 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
KYKazuhiko Yamada
Kazuhiko Yamada
HAHiromi Aono
Hiromi Aono
YHYukio Hosomi
Yukio Hosomi
HOHiroaki Okamoto
Hiroaki Okamoto
TKTerufumi Kato
Terufumi Kato
KWKoshiro Watanabe
Koshiro Watanabe

19 March 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
TTTomoya Tsuchida
Tomoya Tsuchida
YNYuko Nitahara
Yuko Nitahara
SSShotaro Suzuki
Shotaro Suzuki
YKYuko Komase
Yuko Komase
KCKatherine Candray
Katherine Candray
TMTakahide Matsuda
Takahide Matsuda

19 July 2021 in medRxiv
Verified
Preprint
Open access
PDF file
YNYu Nakagama
Yu Nakagama
YKYuko Komase
Yuko Komase
KCKatherine Candray
Katherine Candray
SNSachie Nakagama
Sachie Nakagama
FSFumiaki Sano
Fumiaki Sano
YKYasutoshi Kido
Yasutoshi Kido
We describe the results of testing healthcare workers from a tertiary care hospital in Japan, which had experienced a COVID-19 outbreak during the first peak of the pandemic, for SARS-CoV-2 specific antibody seroconversion. Using two chemiluminescent immunoassays and a confirmatory surrogate virus neutralization test, serological testing unveiled that a surprising 42.2% (27/64) of overlooked COVID-19 diagnoses had occurred when case detection had relied solely on SARS-CoV-2 nucleic acid amplification testing. This undetected portion of the COVID-19 iceberg beneath the surface may potentially have led to silent transmissions and triggered the spread. A questionnaire-based risk assessment was further indicative of exposures to specific aerosol-generating procedures, i.e. non-invasive ventilation, having had conveyed the highest transmission risks and served as the origin of outbreak. Our observations are supportive of a multi-tiered testing approach, including the use of serological diagnostics, in order to accomplish exhaustive case detection along the whole COVID-19 spectrum.

19 September 2022 in medRxiv
Verified
Preprint
Open access
PDF file
YNYu Nakagama
Yu Nakagama
KCKatherine Candray
Katherine Candray
NKNatsuko Kaku
Natsuko Kaku
YKYuko Komase
Yuko Komase
MRMaria-Virginia Rodriguez-Funes
Maria-Virginia Rodriguez-Funes
YKYasutoshi Kido
Yasutoshi Kido
Background The durability and cross-neutralizability of protective antibodies against evolving SARS-CoV-2 variants are primary concerns in mitigating (re-)exposures. The role of antibody maturation, the process whereby selection of higher avidity antibodies augments host immunity, to determine SARS-CoV-2 neutralizability was investigated. Methods Sera collected from SARS-CoV-2 convalescent individuals at 2- or 10-months after recovery, and BNT162b2 vaccine recipients at 3 or 25 weeks post-vaccination, were analyzed. Anti-spike IgG avidity was measured on a urea-treated ELISA platform. Neutralizing ability of antibodies was assessed by surrogate virus neutralization. Fold change between variant and wild-type antigen neutralizability was calculated to infer breadth of neutralizability. Results Compared with early-convalescence, the avidity index of late-convalescent sera was significantly higher (median 37.7 (interquartile range 28.4–45.1) vs. 64.9 (57.5–71.5), p < 0.0001), indicative of progressive antibody maturation extending months beyond acute-phase illness. The urea-resistant, high-avidity fraction of IgG was best predictive of neutralizability (Spearman’s r = 0.49 vs. 0.67 for wild-type; 0.18–0.52 vs. 0.48–0.83 for variants). Higher-avidity convalescent sera showed greater cross-neutralizability against SARS-CoV-2 variants (p < 0.001 for Alpha; p < 0.01 for Delta and Omicron). Vaccinees experienced delayed maturation kinetics, translating to limited breadth of neutralizability at week-25 post-vaccination which was only comparable to that of early-convalescence. Conclusions Avidity maturation grants broader neutralizability that is resilient against emerging SARS-CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish herd immunity, understanding the variable longitudinal evolutions of the two building blocks of ‘hybrid immunity’ is crucial.

1 January 2023
Verified
Journal Article
Closed access
TTTakahiro Tsuburai
Takahiro Tsuburai
AUAyano Tsukune Usuba
Ayano Tsukune Usuba
YKYuko Komase
Yuko Komase
BOBaku Oyama
Baku Oyama
HMHiromi Muraoka
Hiromi Muraoka
TITakeo Inoue
Takeo Inoue